Indeed, glycosphingolipid synthesis was shown to drive pathogenic inflammatory processes in astrocytes in a murine model of secondary progressive MS, and administration of a UGCG inhibitor significantly reduced its progression [56]. This evidence concerns the gene UGCG and myeloid sarcoma.